| 6/5/2018 | CVLM | Impax Laboratories gets tenders of 99.9% of 2% convertibles due 2022
|
| 5/7/2018 | CV | Impax adds Amneal under 2% convertibles, amends conversion right
|
| 3/20/2018 | CV | Impax gives notice of merger event under 2% convertibles due 2022
|
| 11/6/2017 | CVLM | Impax Laboratories gets consents to amend 2% convertibles due 2022
|
| 10/30/2017 | CVLM | Impax Laboratories launches consent solicitation for 2% convertibles
|
| 10/20/2017 | CV | Market Commentary: Convertibles primary quiet for third straight week; Ctrip.com trades again; Impax flat
|
| 10/19/2017 | CV | Market Commentary: Ctrip.com convertibles improve on hedged basis as stock is hit; Impax tracking toward par
|
| 10/19/2017 | CV | Market Commentary: Morning Commentary: Impax extends gains, trading at 97.375; Immune Pharma prices units
|
| 10/18/2017 | CV | Market Commentary: Convertibles trade mildly as stocks rally; Impax extends gains; DISH adds with shares
|
| 10/17/2017 | CV | Market Commentary: Impax Laboratories jumps in active trade after merger news; Herbalife slips; Cemex up
|
| 10/17/2017 | BKCV | Moody’s could raise Impax
|
| 10/17/2017 | CV | Market Commentary: Morning Commentary: Impax Laboratories jumps after merger news, despite lower shares
|
| 8/31/2017 | CV | Market Commentary: Impax Laboratories edges up as shares surge; Ctrip.com lower outright, mixed dollar neutral
|
| 8/22/2017 | BKCVHY | S&P cuts Impax, facilities, notes
|
| 4/13/2017 | BKCV | Moody’s drops Impax
|
| 3/8/2017 | CV | Market Commentary: Pacira deal prices rich, pops above par; Impax improves on strategic review; Chesapeake drops
|
| 3/8/2017 | CV | Market Commentary: Morning Commentary: Pacira deal prices rich, pops above par; Impax rises on strategic review news
|
| 11/23/2016 | BKCVHY | S&P downgrades Impax
|
| 11/4/2016 | CV | Market Commentary: Palo Alto Networks convertibles eyed; sector peer FireEye gains post-earnings; Impax bounces
|
| 8/9/2016 | BKCVIG | S&P cuts Impax convertibles, rates loans BBB-
|
| 8/4/2016 | BKCV | Moody’s assigns Ba2 to Impax facility
|
| 6/22/2016 | BKCV | Moody’s: Impax unchanged following acquisition
|
| 11/9/2015 | CV | Market Commentary: Iconix, Horizon Pharma regain ground after steep losses; Priceline 1% expands on swap
|
| 9/15/2015 | BKCV | Moody’s rates Impax revolver Ba1
|
| 9/15/2015 | BKCV | S&P rates Impax convertibles BB
|
| 9/8/2015 | CV | Market Commentary: Convertibles see better bidders; Impax up outright with FDA news; Dycom, Stericycle on tap
|
| 9/8/2015 | CV | Market Commentary: Morning Commentary: Convertibles see better bidders; Impax Labs jumps with positive FDA news
|
| 8/10/2015 | CV | Market Commentary: Whiting Petroleum improves; Iconix 2.5% convertibles claw back; Impax slips; PTC to price
|
| 6/30/2015 | CV | Market Commentary: Convertibles lower with month-end in focus; Impax slips below par; June primary falters
|
| 6/30/2015 | CV | Impax Laboratories greenshoe exercised, ups 2% convertible notes to $600 million
|
| 6/25/2015 | CV | Market Commentary: New Impax expands on hedge; NorthStar on deck; Gogo, Penn Virginia up outright; Molycorp lower
|
| 6/25/2015 | CV | Market Commentary: New Impax Labs ‘doing fine;’ NorthStar on deck; Molycorp in focus after Chapter 11 filing
|
| 6/25/2015 | CV | New Issue: Impax Labs prices $500 million seven-year convertibles to yield 2%, up 32.5%
|
| 6/24/2015 | CV | Market Commentary: New NRG gains outright, dollar neutral, older NRG in line; CorEnergy edges up; Impax launches
|
| 6/24/2015 | CV | Impax Labs plans to price $500 million seven-year convertibles to yield 1.5%-2%, up 32.5$-37.5%
|
| 12/3/2008 | CV | Impax Labs buys back $62.25 million 3.5% convertibles at discount
|
| 7/8/2005 | BTCVPP | New Issue: Impax Labs sells $75 million 3.5% notes, convert at $20.695
|
| 6/28/2005 | CV | Market Commentary: Lonza issue emerges; Walter better as takeover anxiety eases; Interpublic holders to get windfall payment
|
| 6/27/2005 | CV | Market Commentary: Lear eases on layoffs; airlines dive on oil spike; Weatherford watched as put nears; CV, Impax deals eyed
|
| 6/27/2005 | BTCVPP | New Issue: Impax Labs sells $75 million convertible notes with 3.5% coupon to Highbridge
|
| 6/22/2005 | CV | Market Commentary: CV Therapeutics, Evergreen Solar launch after quiet day; Reckson deal upsized, reoffered in thin trade
|
| 6/20/2005 | BTCV | Impax Laboratories augments facility to $37 million
|
| 6/20/2005 | CV | Market Commentary: New Calpine issue boosts sister securities; airlines hold up; convertibles overall lower with bonds
|
| 6/8/2005 | CV | Market Commentary: ImClone, Impax brighten as convertible players eye firmer market; GM extends gains
|
| 6/3/2005 | CV | Market Commentary: Symmetricom prices wide, still breaks below par; Cephalon off to 98; Impax bid up; Doral eyed
|
| 6/2/2005 | CV | Market Commentary: Cephalon suffers in aftermarket; Joy Global pulled; Symmetricom at bat; Elan retreats on drug news
|
| 5/27/2005 | CV | Market Commentary: Computer Associates accounting ills resurface; CompuCredit seen; Impax Labs holders hope for fee
|
| 4/11/2005 | CV | Market Commentary: El Paso at bat with sweeter terms; Nabi emerges; Ford plummets in wake of warning; Impax steadies
|
| 5/5/2004 | CV | Market Commentary: Oscient Pharmaceuticals hits par 1/8 bid on first day of trading
|
| 3/31/2004 | CV | New Issue: Impax Labs upsized $82 million convertible yields 1.25%, up 30%
|
| 3/31/2004 | CV | Market Commentary: Amylin at 102 bid before pricing aggressively; Caesars dips below par; Kerzner bets push past 101
|
| 3/30/2004 | CV | Impax Labs $75 million convertible talked at 1.25-1.75%, up 25-30%
|
| 3/30/2004 | CV | Market Commentary: Caesars, Kerzner, Impax Labs on tap with FelCor, Regal-Beloit; ON Semicon, Amylin launched
|
